SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.80+0.1%1:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stephen who wrote (7838)6/9/1999 4:34:00 PM
From: Anthony Wong  Read Replies (3) of 9523
 
Analysts comments from the latest Bloomberg update (Stephen, the impact on earnings according to Tighe is 2 cents for 1999):

Problems with Trovan have dimmed high hopes for the drug.
Sales of the drug, once expected to reach as much as $1 billion a
year, now could peak at around $300 million, said independent
analyst Hemant Shah.

''This is a highly competitive market, and one can replace
Trovan with something else relatively easily,'' he said. ''There
are so many antibiotics that can do what Trovan does.''

Merrill Lynch & Co. analyst Steven Tighe said he was
dropping his estimate for 1999 sales of the drug to $140 million
from $300 million and cutting his earnings estimate for all of
1999 to $2.47 a share from $2.49.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext